64850-910 : Isradipine 2.5 mg Oral Capsule


NDC: 64850-910
Labeler: Elite Laboratories, Inc.
Product Type: Human Prescription Drug
Drug Name:  Isradipine
Dosage Form: Oral Capsule
Application #: ANDA077169
Rev. Date: 


NDC Package Codes:

  • 64850-910-01: 100 CAPSULE IN 1 BOTTLE (64850‑910‑01)
  • 64850-910-05: 500 CAPSULE IN 1 BOTTLE (64850‑910‑05)

Active Ingredients:

  • Isradipine

Dosage Strength:

  • 2.5 mg

Pharmaceutical Classes:

  • Calcium Channel Antagonists [MoA]
  • Dihydropyridine Calcium Channel Blocker [EPC]
  • Dihydropyridines [CS]

Related Products:

Based on records with the same trade name.
  • 64850-911 Isradipine 5 mg Oral Capsule by Elite Laboratories, Inc.
  • 16252-539 Isradipine 2.5 mg Oral Capsule by Cobalt Laboratories
  • 16252-540 Isradipine 5 mg Oral Capsule by Cobalt Laboratories
  • 42291-062 Isradipine 2.5 mg Oral Capsule by Avkare
  • 42806-263 Isradipine 2.5 mg Oral Capsule by Epic Pharma, LLC
  • 42806-264 Isradipine 5 mg Oral Capsule by Epic Pharma, LLC
  • 50268-454 Isradipine 2.5 mg/1 Oral Capsule by Avpak
  • 50268-455 Isradipine 5 mg/1 Oral Capsule by Avpak
  • 60429-385 Isradipine 2.5 mg Oral Capsule by Golden State Medical Supply, Inc.
  • 60429-386 Isradipine 5 mg Oral Capsule by Golden State Medical Supply, Inc.
  • 68151-1333 Isradipine 5 mg Oral Capsule by Carilion Materials Management
  • 68462-807 Isradipine 2.5 mg Oral Capsule by Glenmark Pharmaceuticals Inc., USA
  • 68462-808 Isradipine 5 mg Oral Capsule by Glenmark Pharmaceuticals Inc., USA

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 64850-910 QR Code

< Prev: 64850-900Next: 64850-911 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.